endpoints.news/asco26-revol... Experimental drug for ppl w an advanced form of pancreatic cancer has dropped risk of death by 60%, lowered pain & increased quality of life compared with chemotherapy. It targets RAS proteins - mutated in 90% of pancreatic cancers & extremely difficult to target.
When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.
